QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:RNA

Avidity Biosciences Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$22.23
-0.73 (-3.18 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.22
Now: $22.23
$23.76
50-Day Range N/A
52-Week Range
$4.12
Now: $22.23
$22.80
Volume465,272 shs
Average Volume260,559 shs
Market Capitalization$834.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
Avidity Biosciences logo

Headlines

Avidity Biosciences Has A Promising RNA Therapy Platform
January 14, 2021 |  seekingalpha.com
Is RNA A Good Stock To Buy According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
Avidity Biosciences EPS misses by $0.01, beats on revenue
November 10, 2020 |  seekingalpha.com
Insiders Roundup: Axis Capital, HD Supply
June 19, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RNA
CUSIPN/A
Phone858-401-7900
Employees42
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$834.29 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

461st out of 1,971 stocks

Pharmaceutical Preparations Industry

223rd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Receive RNA News and Ratings via Email

Sign-up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avidity Biosciences (NASDAQ:RNA) Frequently Asked Questions

Is Avidity Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Avidity Biosciences?

Wall Street analysts have given Avidity Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avidity Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Avidity Biosciences
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) posted its earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.06. The biotechnology company had revenue of $1.75 million for the quarter.
View Avidity Biosciences' earnings history
.

What price target have analysts set for RNA?

4 brokerages have issued twelve-month price objectives for Avidity Biosciences' shares. Their forecasts range from $34.00 to $60.00. On average, they expect Avidity Biosciences' share price to reach $43.33 in the next twelve months. This suggests a possible upside of 94.9% from the stock's current price.
View analysts' price targets for Avidity Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Avidity Biosciences' key executives?

Avidity Biosciences' management team includes the following people:
  • Dr. Troy Edward Wilson, Co-Founder & Chairman (Age 52, Pay $664.92k)
  • Ms. Sarah Boyce, Pres, CEO & Director (Age 49, Pay $154.26k)
  • Dr. Arthur A. Levin, Chief Scientific Officer (Age 67, Pay $543.01k)
  • Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 71)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 55)
  • Mr. Joseph Baroldi, Chief Operating Officer (Age 43)
  • Dr. W. Michael Flanagan Ph.D., Chief Technical Officer
  • Dr. John W. Wallen III, VP of Intellectual Property & Gen. Counsel (Age 63)
  • Ms. Teresa McCarthy, Chief HR Officer

Who are some of Avidity Biosciences' key competitors?

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), 589378 (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.41%), Alethea Capital Management LLC (4.19%), Federated Hermes Inc. (3.81%), Price T Rowe Associates Inc. MD (2.52%), Victory Capital Management Inc. (2.27%) and Aaron Wealth Advisors (1.40%).
View institutional ownership trends for Avidity Biosciences
.

Which major investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Northern Trust Corp, Dupont Capital Management Corp, and Candriam Luxembourg S.C.A..
View insider buying and selling activity for Avidity Biosciences
or view top insider-selling stocks.

Which major investors are buying Avidity Biosciences stock?

RNA stock was purchased by a variety of institutional investors in the last quarter, including Alethea Capital Management LLC, BlackRock Inc., Aaron Wealth Advisors, TCW Group Inc., Federated Hermes Inc., Los Angeles Capital Management LLC, Victory Capital Management Inc., and Hamilton Lane Advisors LLC.
View insider buying and selling activity for Avidity Biosciences
or or view top insider-buying stocks.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $22.23.

How much money does Avidity Biosciences make?

Avidity Biosciences has a market capitalization of $834.29 million.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 42 workers across the globe.

What is Avidity Biosciences' official website?

The official website for Avidity Biosciences is www.aviditybiosciences.com.

Where are Avidity Biosciences' headquarters?

Avidity Biosciences is headquartered at 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.